![David Segarra](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de David Segarra
Sociétés | Poste | Début | Fin |
---|---|---|---|
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Directeur/Membre du Conseil | 01/01/2014 | - |
Directeur Général | 01/01/2014 | - | |
Fondateur | 01/01/2014 | - |
Historique de carrière de David Segarra
Anciens postes connus de David Segarra
Sociétés | Poste | Début | Fin |
---|---|---|---|
Aptus Biotech SL
![]() Aptus Biotech SL BiotechnologyHealth Technology Aptus Biotech SL develops drug candidates using its aptamer platform. It is a biotechnology company specializing in the development and customization of Aptamers fully adapted to the needs of each application. The firm’s product Aptateca, offers a catalog of aptamers. The company was founded by David Segarra and María Eugenia Zarabozo in 2010 and is headquartered in Madrid, Spain. | Directeur Général | 01/01/2010 | - |
Fondateur | 01/01/2010 | - |
Statistiques
Internationale
Espagne | 3 |
Opérationnelle
Chief Executive Officer | 2 |
Founder | 2 |
Director/Board Member | 1 |
Sectorielle
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Aptus Biotech SL
![]() Aptus Biotech SL BiotechnologyHealth Technology Aptus Biotech SL develops drug candidates using its aptamer platform. It is a biotechnology company specializing in the development and customization of Aptamers fully adapted to the needs of each application. The firm’s product Aptateca, offers a catalog of aptamers. The company was founded by David Segarra and María Eugenia Zarabozo in 2010 and is headquartered in Madrid, Spain. | Health Technology |
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Health Technology |
- Bourse
- Insiders
- David Segarra
- Expérience